Gender Differences and Immunotherapy Outcome in Advanced Lung Cancer

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Lung cancer is a leading cause of cancer death globally, with notable differences observed between sexes, even in non-smokers.
• Gender disparities in lung cancer are influenced by a complex interplay of genetic, environmental, hormonal, and immune system factors.
• The immune system's role in cancer progression and response to treatments like immunotherapy is increasingly recognized, with documented sex-based variations.

Purpose of the Study:

• To review current data on gender disparities in the immune system of healthy individuals and lung cancer patients.
• To examine studies investigating sex differences in response to lung cancer immunotherapy.

Main Methods:

• Literature review of recent scientific data.
• Analysis of studies focusing on gender disparities in immunity and lung cancer.
• Examination of research on sex differences in immunotherapy response.

Main Results:

• Significant gender differences exist in immune system function and lung cancer development.
• These disparities impact cancer evolution and response to oncological treatments, particularly immunotherapy.
• Existing research suggests that findings from one sex may not be directly applicable to the other.

Conclusions:

• Gender is a critical factor influencing lung cancer pathogenesis and treatment outcomes.
• Recognizing and addressing sex-based differences in immunity is essential for personalized lung cancer therapy.
• Further research into gender disparities in immunotherapy is needed for improved clinical strategies.